Results 141 to 150 of about 41,454 (219)

Ebola vaccines: we have options [PDF]

The Lancet Infectious Diseases, 2016
openaire   +2 more sources

First Ebola vaccine approved [PDF]

Nature Biotechnology, 2020
openaire   +1 more source

Aligning health, industry, and innovation through public procurement. [PDF]

Eur J Public Health
da Fonseca EM, Shadlen KC.
europepmc   +1 more source

Sex Differences in Response to Viral Vector Vaccines-Implications for Future Vaccine Design. [PDF]

Immunol Rev
Grewe I, Zoran T, Addo MM.
europepmc   +1 more source

Funding the global control of bird flu. [PDF]

, 2006
Roberts, Jennifer A
core   +1 more source

Effect of the time of day for vaccination on the immune response to Ebola Virus Disease vaccines: A modeling study from PREVAC randomized trial. [PDF]

PLoS Negl Trop Dis
Kpetigo AD, Alexandre M, Camara A, Beavogui A, Doumbia S, Kieh M, Leigh B, Sow S, Wittkop L, Soutthiphong AA, Berry IM, Fleck S, Akoo P, Hamze B, Watson-Jones D, Kuhn JH, Greenwood B, Richert L, Yazdanpanah Y, Lévy Y, Thiébaut R, Prague M, PREVAC Study Team, Lhomme E.   +23 more
europepmc   +1 more source

Evidence for Neuroinvasive Lassa Virus Infection in Pediatric Patients: Initial Findings and Implications. [PDF]

J Infect Dis
Platt AP, Chertow DS.
europepmc   +1 more source

Acceptability of the Ebola vaccine in the sub-Saharan African population: A systematic review and meta-analysis. [PDF]

BMC Infect Dis
Matangi B, Matondo P, Kayembe B, Okolo A, Tawaba D, Kinuka A, Mangala D, Odio O, Mayasi N, Lukiana T, Mandina M, Pindi T, Longokolo M, Mbula M, Situakibanza H, Bepouka B.   +15 more
europepmc   +1 more source

Nigeria's post-COVID-19 vaccine manufacturing ambitions: Opportunities and regional implications. [PDF]

J Public Health Afr
Oyebanji O, Falade O, Kristensen F, Heymann D, Kampmann B.   +4 more
europepmc   +1 more source

Special Issue: Novel Vaccines and Vaccine Technologies for Emerging Infections. [PDF]

Vaccines (Basel)
Chen W, Li X, Kamen AA.
europepmc   +1 more source